PriZm Therapeutics
Late-stage clinical biotechnology company focused on developing therapies for ultra-rare pediatric orphan diseases, principally advancing a small-molecule thyroid hormone analog (SRW101/DITPA) for MCT8 deficiency (Allan-Herndon-Dudley syndrome). The company has licensed the lead program from an academic institution, is preparing a registration (phase III) trial, and holds orphan and rare pediatric regulatory designations.
Industries
Nr. of Employees
small (1-50)
PriZm Therapeutics
Products
SRW101 (DITPA)
An investigational small-molecule thyroid hormone analog (3,5-diiodothyropropionic acid) being developed as an oral formulation intended to increase central nervous system T3 activity via alternate transporters and lower peripheral serum T3 in MCT8 deficiency.
SRW101
An investigational drug by PriZm Therapeutics in phase III pivotal registration clinical trial for patients with AHDS (Allan-Herndon-Dudley Syndrome).
SRW101 (DITPA)
An investigational small-molecule thyroid hormone analog (3,5-diiodothyropropionic acid) being developed as an oral formulation intended to increase central nervous system T3 activity via alternate transporters and lower peripheral serum T3 in MCT8 deficiency.
SRW101
An investigational drug by PriZm Therapeutics in phase III pivotal registration clinical trial for patients with AHDS (Allan-Herndon-Dudley Syndrome).
Services
Planning and execution support for a phase III pivotal registration clinical trial for an investigational therapy in an ultra-rare pediatric disease.
Planning and execution support for a phase III pivotal registration clinical trial for an investigational therapy in an ultra-rare pediatric disease.
Expertise Areas
- Clinical trial management
- Rare pediatric disease therapeutics
- Endocrinology and thyroid hormone transport disorders
- Small-molecule drug development
Key Technologies
- Small-molecule thyroid hormone analogs (DITPA)
- Alternate transporter-mediated blood–brain barrier delivery
- Thyroid hormone receptor binding assays
- Preclinical animal models (Mct8-deficient mice)
News & Updates
Coverage naming the company as the winner of BIO's Seed-Stage Start-Up Stadium.
Recognized as BIO’s Seed-Stage Start-Up Stadium winner.
Company press release announcing the award and related company activities.
Coverage naming the company as the winner of BIO's Seed-Stage Start-Up Stadium.
Recognized as BIO’s Seed-Stage Start-Up Stadium winner.
Company press release announcing the award and related company activities.